Peking University Health Science Center (PKUHSC)

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection	Digestive System Diseases, Digestive System Neoplasms, Fibrosis, Hepatic Insufficiency, Liver Neoplasms, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Steatohepatitis, cirrhosis of liver, fatty liver disease, liver cancer, liver disorder, liver failure, neoplasm	Recruiting	Phase 1 / Phase 2	2025-07-08		NCT07053488
CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk	Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, chronic kidney disease, chronic renal failure syndrome, epithelial neoplasm, kidney cancer, kidney disorder, kidney failure, kidney neoplasm, neoplasm, renal cell carcinoma, urinary system disorder	Recruiting	Phase 1 / Phase 2	2025-07-08		NCT07053462

Clinical trials